Lexicon Pharmaceuticals (NASDAQ:LXRX) announced its earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.26) earnings per share.
Shares of LXRX traded down $0.36 during mid-day trading on Friday, reaching $3.52. The stock had a trading volume of 1,316,800 shares, compared to its average volume of 1,292,482. The firm has a market cap of $419.77 million, a price-to-earnings ratio of -3.09 and a beta of 0.95. The business has a fifty day moving average of $3.52 and a 200 day moving average of $4.21. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $9.15.
Several analysts recently issued reports on the stock. Stifel Nicolaus lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the company from $10.00 to $4.00 in a research report on Monday, July 29th. Citigroup lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their target price for the company from $3.00 to $4.00 in a research report on Friday. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Saturday. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, Wedbush restated a “buy” rating and set a $17.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, October 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.45.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: How to invest using market indexes
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.